May 21, 2024 01:41 PM EDT
Pharma
FDA+

Bris­tol My­er­s' sub­cu­ta­neous ver­sion of Op­di­vo gets ear­li­er PDU­FA date

Katherine Lewin

News Reporter

The FDA has short­ened the time­line for com­ing to a de­ci­sion on Bris­tol My­ers Squibb’s sub­cu­ta­neous ver­sion of its block­buster PD-1 in­hibitor Op­di­vo.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

A service from the Financial Times